Cargando…
Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach
The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an unprecedented global health problem, causing more than 20 million infections and more than 900,000 deaths (September 2020). The SARS-CoV-2 infection, known as COVID-19, has various clinical presentations, from asymptoma...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947499/ https://www.ncbi.nlm.nih.gov/pubmed/33717596 http://dx.doi.org/10.21037/jtd-20-3062 |
_version_ | 1783663241888530432 |
---|---|
author | García-Ortega, Alberto de la Rosa, David Oscullo, Grace Castillo-Villegas, Diego López-Reyes, Raquel Martínez-García, Miguel Ángel |
author_facet | García-Ortega, Alberto de la Rosa, David Oscullo, Grace Castillo-Villegas, Diego López-Reyes, Raquel Martínez-García, Miguel Ángel |
author_sort | García-Ortega, Alberto |
collection | PubMed |
description | The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an unprecedented global health problem, causing more than 20 million infections and more than 900,000 deaths (September 2020). The SARS-CoV-2 infection, known as COVID-19, has various clinical presentations, from asymptomatic or mild catarrhal processes to severe pneumonia that rapidly progresses to acute respiratory distress syndrome (ARDS) and multiple organ failure. In the last few months, much scientific literature has been devoted to descriptions of different aspects of the coagulation disorders and arterial and venous thrombotic complications associated with COVID-19, particularly venous thromboembolism (VTE). These studies have revealed that SARS-CoV-2 could lead to a prothrombotic state reflecting the high cumulative incidence of associated thrombotic events, particularly in patients admitted to intensive care units (ICUs). As regards the coagulopathy observed in association with SARS-CoV-2 infection, the mechanisms that activate coagulation have been hypothesized as being linked to immune responses, through the release of pro-inflammatory mediators that interact with platelets, stimulate the expression of tissue factor, induce an upregulation of plasminogen activator inhibitor-1, suppress the fibrinolytic system and lead to endothelial dysfunction, triggering thrombogenesis. D-dimer elevation has been recognized as a useful biomarker of poor prognosis, although the best cut-off point for predicting VTE in COVID-19 patients has still not been clarified. This review will try to update all the available scientific information on this important topic with enormous clinical and therapeutic implications. |
format | Online Article Text |
id | pubmed-7947499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-79474992021-03-12 Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach García-Ortega, Alberto de la Rosa, David Oscullo, Grace Castillo-Villegas, Diego López-Reyes, Raquel Martínez-García, Miguel Ángel J Thorac Dis Review Article The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an unprecedented global health problem, causing more than 20 million infections and more than 900,000 deaths (September 2020). The SARS-CoV-2 infection, known as COVID-19, has various clinical presentations, from asymptomatic or mild catarrhal processes to severe pneumonia that rapidly progresses to acute respiratory distress syndrome (ARDS) and multiple organ failure. In the last few months, much scientific literature has been devoted to descriptions of different aspects of the coagulation disorders and arterial and venous thrombotic complications associated with COVID-19, particularly venous thromboembolism (VTE). These studies have revealed that SARS-CoV-2 could lead to a prothrombotic state reflecting the high cumulative incidence of associated thrombotic events, particularly in patients admitted to intensive care units (ICUs). As regards the coagulopathy observed in association with SARS-CoV-2 infection, the mechanisms that activate coagulation have been hypothesized as being linked to immune responses, through the release of pro-inflammatory mediators that interact with platelets, stimulate the expression of tissue factor, induce an upregulation of plasminogen activator inhibitor-1, suppress the fibrinolytic system and lead to endothelial dysfunction, triggering thrombogenesis. D-dimer elevation has been recognized as a useful biomarker of poor prognosis, although the best cut-off point for predicting VTE in COVID-19 patients has still not been clarified. This review will try to update all the available scientific information on this important topic with enormous clinical and therapeutic implications. AME Publishing Company 2021-02 /pmc/articles/PMC7947499/ /pubmed/33717596 http://dx.doi.org/10.21037/jtd-20-3062 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article García-Ortega, Alberto de la Rosa, David Oscullo, Grace Castillo-Villegas, Diego López-Reyes, Raquel Martínez-García, Miguel Ángel Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach |
title | Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach |
title_full | Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach |
title_fullStr | Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach |
title_full_unstemmed | Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach |
title_short | Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach |
title_sort | coagulation disorders and thromboembolic disease in covid-19: review of current evidence in search of a better approach |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947499/ https://www.ncbi.nlm.nih.gov/pubmed/33717596 http://dx.doi.org/10.21037/jtd-20-3062 |
work_keys_str_mv | AT garciaortegaalberto coagulationdisordersandthromboembolicdiseaseincovid19reviewofcurrentevidenceinsearchofabetterapproach AT delarosadavid coagulationdisordersandthromboembolicdiseaseincovid19reviewofcurrentevidenceinsearchofabetterapproach AT oscullograce coagulationdisordersandthromboembolicdiseaseincovid19reviewofcurrentevidenceinsearchofabetterapproach AT castillovillegasdiego coagulationdisordersandthromboembolicdiseaseincovid19reviewofcurrentevidenceinsearchofabetterapproach AT lopezreyesraquel coagulationdisordersandthromboembolicdiseaseincovid19reviewofcurrentevidenceinsearchofabetterapproach AT martinezgarciamiguelangel coagulationdisordersandthromboembolicdiseaseincovid19reviewofcurrentevidenceinsearchofabetterapproach |